France-based Idinvest Partners has acquired a stake in KLS Partners. At the same time KLS is launching its second fund Kurma Biofund II.
PRESS RELEASE
In keeping with their history of close collaboration, the companies announced today that Idinvest Partners was acquiring a stake in KLS Partners. This new investment coincides with increased management participation in the equity of KLS Partners, as well as the exit of Natixis Private Equity.
According to Christophe Bavière, CEO of Idinvest Partners, and Benoist Grossmann, Managing Partner, “This investment comes after 10 years of our teams working together. When Thierry Laugel and Rémi Droller, two former Idinvest Partners employees, founded KLS Partners in 2010, they continued providing insight on Idinvest Partners’ health sector investments. We are delighted to be able to pursue this partnership, which rounds out Idinvest’s own ample expertise in digital and cleantech.”
Thierry Laugel and Rémi Droller, Managing Partners of Kurma Life Sciences Partners, announced, “We share, with the teams at Idinvest Partners, the same vision of financing innovative businesses and this is the logical next step after years of superb teamwork.”
At the same time Kurma is launching its recently announced second fund (Kurma Biofund II), the first venture capital fund dedicated to financing innovation with a diversified strategy and significant exposure to rare diseases, sponsored by Idinvest Partners alongside CDC Entreprises (BPIfrance), GSK and NEA.
About Idinvest Partners
With €4 billion under management and 40 staff, Idinvest Partners is a leading pan-European manager focused on the middle market segment. Idinvest Partners has developed several complementary areas of expertise including investments in innovative European start-ups, primary, secondary and mezzanine investments in European non-listed companies, and private equity consulting. Founded under the name AGF Private Equity in 1997, Idinvest Partners was formerly part of the Allianz Group until 2010 when it joined forces with IDI Group to become independent.
About Kurma Life Sciences Partners
Founded in July 2009, KLS Partners is a key European player in venture capital, development capital and technology transfer in the field of life sciences (biotechnologies, health, nutrition, environmental sciences), notably through the Kurma Biofund venture capital funds and strategic partnerships with forefront European biotechnology medical research centres. www.kls-partners.com
Contact: Nicolas Merigeau Tel: +33(0)1 44 51 94 98 / email: nmerigeau@newcap.fr
Citigate Dewe Rogerson
Paris Office
18 rue de Londres – 75009 Paris
Tel +33 1 53 32 78 94
Mob +33 6 66 58 84 28
Fax +33 1 53 32 78 96
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.